RPRX | Royalty Pharma plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	33.06 - 33.60
52 Week Range	24.05 - 33.69
Beta	0.48
Implied Volatility	31.94%
IV Rank	36.59%
Day's Volume	2,835,602
Average Volume	3,865,413
Shares Outstanding	433,325,000
Market Cap	14,507,721,000
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-16

Valuation
Profitability
Growth
Health
P/E Ratio	17.53
Forward P/E Ratio	6.40
EPS	1.91
1YR Price Target	48.50
Dividend Yield	2.64%
Dividend Per Share	0.88
Dividend ExDate	2023-08-17
Dividend PayDate	2023-09-15
Employees	75
Country	USA
Website	RPRX

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

RPRX's peers: ADPT, PRME, RPHM, DNA, OCEA, VECT, KNTE, IKNA, ASND, APLS, BGNE, AKRO, BPMC, IOVA, CVAC, MDGL, MRTX, ISEE, AMLX, KRTX, DAWN

*Chart delayed

Analyzing fundamentals for RPRX we got that it has average fundamentals where Valuation is considered to be significantly undervalued, Profitability is wealthy, Growth is good and Health is weak. For more detailed analysis please see RPRX Fundamentals page.

Watching at RPRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RPRX Technicals page.